ALPS Medical Breakthroughs ETF
A primer for investors

The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of the Poliwogg Medical Breakthroughs Index. That index aims to capture research and development opportunities in the biotechnology and pharmaceutical industries.
Big Pharma: patent cliff ends era of blockbuster drugs

According to IMS HealthCare Informatics, global spending on brand name (patent-protected) drugs is projected to grow less than 5% cumulatively between 2012 and 2017, while spending on generic drugs is forecast to increase more than 60% over the same time (Figure 1). This is due to the so-called “patent cliff”, in which many of the blockbuster drugs from the 1990s and 2000s have lost patent protections in the past few years, a trend which will continue through the end of the decade.

When a blockbuster drug goes off-patent, annual sales often fall 75% or more, as they are quickly replaced by much cheaper generics. Established, large drug companies (a.k.a. Big Pharma) have been left scrambling to replenish their pipelines, often by acquiring smaller, innovative biotechnology companies.

Biotech: rapid spending growth, limited generic competition

One area of promise is the biotechnology industry. Unlike traditional mass-market pharmaceuticals which use chemical-based synthetic products to create “small molecule” drugs, biotech therapies manipulate microorganisms like bacteria or biological substances such as proteins and enzymes to treat diseases.

IMS predicts global spending on biologics will increase from $169 billion in 2012 to $221 billion in 2017 (Figure 2), or about 31%. Furthermore, biosimilars—essentially biotech’s version of generic drugs—are projected to grow from 1.4% of total spending in 2012, but will still only represent about 2-5% of overall spending by 2017 based on these estimates. This makes biotech firms fertile targets for acquisition by larger firms needing differentiated therapies for which they can charge monopoly (i.e., patent-protected) prices.
New drug research and development—whether for biologics or traditional pharmaceuticals—is a risky, expensive, and very lengthy process. The development process looks like a funnel, where at every stage the number of NMEs (New Molecular Entities) that successfully pass to the next phase decreases (Figure 3). The vast majority of NMEs tried fail to ever reach the consumer, and the ones that do have often taken a decade or more, and many millions of dollars in research and trial spending.

**Figure 3: New Drug Development Cone**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Research</td>
<td>Drug discovery. Thousands of compounds tested. May take years.</td>
</tr>
<tr>
<td>Pre-Clinical Trials</td>
<td>Tests on non-human subjects to gather efficacy, toxicity info, etc. 4+ years</td>
</tr>
<tr>
<td>Phase I</td>
<td>Test of drug on healthy volunteers for safety and dose-ranging. 20-100 people and several months</td>
</tr>
<tr>
<td>Phase II</td>
<td>Testing of drug on patients to assess efficacy and safety. 100-300 participants, up to 2 years</td>
</tr>
<tr>
<td>Phase III</td>
<td>Determines a drug’s therapeutic effect; at this point, the drug is presumed to have some effect. 1,000-3,000 participants, 1-4 years</td>
</tr>
<tr>
<td>FDA Application</td>
<td>About 1½ years</td>
</tr>
</tbody>
</table>

Given the lengthy process and high rate of failure for new drug development—combined with the fact that the era of the “blockbuster” is drawing to a close—it is difficult for large pharmaceutical companies to maintain a research and development pipeline sufficiently robust to replace revenue being lost to generic manufacturers.

In this environment, it makes sense to simply acquire promising new therapies being developed by smaller innovative biotechnology firms, through licensing arrangements or merger activity. Figure 4 shows the number of license deals completed by firms in the Poliwogg Medical Breakthroughs Index (“PMBI”) as licensor. Data such as this is naturally bumpy, but the three-year moving average shows clearly the trend in deal activity, which nearly tripled between 2004-09 in the run-up to the patent cliff, and since appears to have expanded at a more moderate pace, but still averaging about 40 deals in each of the past two years.

**Figure 4: PMBI Number of License Deals as Licensor**

Source: BioPharm Insight. Based on current PMBI constituents as of 10/15/2017.
Poliwogg Medical Breakthroughs Index: A Primer for Investors

About the Index

Description

The Poliwogg Medical Breakthroughs Index ("PMBI") seeks to capture research and development opportunities in the pharmaceutical industry. PMBI consists of small-cap and mid-cap pharmaceutical and biotechnology stocks listed on US stock exchanges that have one or more drugs in either Phase II or Phase III US FDA clinical trials.

Inclusion criteria

Basic selection: U.S. listed biotech or pharmaceutical firm with 1 or more drugs in Phase II or Phase III FDA clinical trials

Market Cap: Between $200 million and $5 billion

Liquidity: Avg. daily volume > $1 million

Weighting: Modified market cap, max 4.5% at rebalance

Sustainability: Enough cash for 24 months at current burn rate

Index comparison

Compared to the widely-followed NASDAQ Biotechnology Index ("NBI"), PMBI is tilted to small- and mid-cap firms, which as we’ll show on the next slide is where the innovation happens, or at least where a larger portion of investors’ dollars are spent on R&D. In contrast, the companies in NBI are much larger—about 17x the market cap of their counterparts in PMBI on average—and being more established players they spend more heavily on operations.

Finally, although the two indices do have constituents in common, by weight these positions overlap by only 14.4% of each index. This means that 85.6% of exposures in one are not duplicated in the other.

<table>
<thead>
<tr>
<th>PMBI</th>
<th>NBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of constituents</td>
<td>91</td>
</tr>
<tr>
<td>Wgt avg. market cap</td>
<td>$2.4 billion</td>
</tr>
<tr>
<td>Weight of Top 10</td>
<td>35.1%</td>
</tr>
<tr>
<td>Large cap (&gt;10bn)</td>
<td>0%</td>
</tr>
<tr>
<td>Mid cap (2-10bn)</td>
<td>53.7%</td>
</tr>
<tr>
<td>Small cap (&lt;2bn)</td>
<td>46.3%</td>
</tr>
<tr>
<td>Overlap by weight</td>
<td>14.4% for both</td>
</tr>
</tbody>
</table>

Note: As of 9/30/2017. Subject to change.

Top 10 Holdings

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLUEBIRD BIO</td>
<td>4.7%</td>
</tr>
<tr>
<td>EXELIXIS</td>
<td>4.2%</td>
</tr>
<tr>
<td>GALAPAGOS NV</td>
<td>3.9%</td>
</tr>
<tr>
<td>ACADIA PHARMACEUTICALS</td>
<td>3.5%</td>
</tr>
<tr>
<td>TARO PHARMACEUTICAL IND.</td>
<td>3.4%</td>
</tr>
<tr>
<td>BEIGENE LTD.</td>
<td>3.3%</td>
</tr>
<tr>
<td>FIBROGEN</td>
<td>3.2%</td>
</tr>
<tr>
<td>AKORN</td>
<td>3.1%</td>
</tr>
<tr>
<td>OPKO HEALTH</td>
<td>2.9%</td>
</tr>
<tr>
<td>NEKTAR THERAPEUTICS</td>
<td>2.8%</td>
</tr>
</tbody>
</table>

Source: AltaVista Research as of 9/30/2017. Note: PMBI is Poliwogg Medical Breakthroughs Index; NBI is NASDAQ Biotechnology Index. One cannot invest directly in an index.

Figure 5: PMBI Drug Development Pipeline

Source: BioPharm Insight as of 10/15/2017

Figure 6: PMBI Phase II Trials by Disease

Source: BioPharm Insight as of 10/15/2017
Poliwogg Medical Breakthroughs Index: A Primer for Investors

Index comparison

Large cap Biotech firms typically focus more on marketing and distribution, less on innovation

The more established firms in the NASDAQ Biotech Index spent an average of 8.8% of their market cap on non-R&D operating expenses (i.e., manufacturing, SG&A expenses, etc.) over the most recent four quarters, while the earlier-stage firms in the Poliwogg Medical Breakthroughs Index spent 11.0%, or 25% more on a relative basis. At the same time, firms in PMBI spent an amount equal to 6.2% of market cap on Research & Development, 44% more than did firms in the NASDAQ index, which spent an amount equal to 4.3% of market cap. While these differences may seem small, the results in terms of clinical trials—and therefore potential new products—is startling when measured in relation to costs to the investor.

Figure 7: Non-R&D Operating Expense as a Percentage of Market Cap

Figure 8: Research & Development Expense as a Percentage of Market Cap

Source: AltaVista Research as of 9/30/2017, based on most recent four quarters data available

Investors in firms in the Poliwogg Medical Breakthroughs Index may gain exposure to clinical trials for considerably cheaper than do investors in firms comprising the NASDAQ Biotech Index. For example, as of October 15, 2017 the market-cap to Phase III clinical trials ratio for firms in PMBI equated to $776 million per clinical trial; that figure for firms in NBI was $2.2 billion (Figure 9). On average, investors paid about 2.9x as much per clinical trial for firms in the NASDAQ Biotech Index as they did for firms in the Poliwogg Medical Breakthroughs Index.

Figure 9: Market Cap-to-Clinical Trials ($mns)

Source: BioPharm Insight and AltaVista Research as of 10/15/2017

Granted, investors in firms comprising the NASDAQ Biotech Index are also acquiring more established manufacturing and distribution operations. This means products with real cash flows that are easier for investors to value and which can fund future developments—and acquisitions. This reduces their risk of failure and therefore their riskiness as investments.

Nonetheless, in terms of acquiring pure innovative potential in the form of clinical drug trials, firms in the Poliwogg Medical Breakthroughs Index were the less expense route according to the October 15, 2017 data. Investors might in some ways compare this to venture capitalists in Silicon Valley with a stable of social media start-ups hoping to strike app gold and be acquired by one of the Tech giants. In this case, striking gold with promising results from clinical trials can lead to acquisition by one of the large established players in the biotech or traditional pharmaceuticals industries.
Biotech Investing

Tough industry for stock pickers

Biotechnology is a particularly difficult industry for stock pickers, making a passive index-based investment more appealing as an alternative. Among the reasons the industry is challenging for stock pickers:

**High Failure Rate:** The vast majority of new compounds fail in clinical trials, and many companies are never able to develop commercially viable products. This tends to produce more "losers" than "winners" making it unfertile ground for stock selection.

**Non-Traditional Metrics:** Biotech stocks often trade on very high (or meaningless) multiples of revenue, earnings and other traditional measures, since many companies are not profitable. They often trade on the perceived "promise" of drugs still in development.

**Specialized Knowledge:** Most investors without medical training have limited ability to assess whatever public information may exist about early trial results. Investors cannot conduct channel checks or evaluate products themselves, but must wait for unpredictable trial results.

**Extreme volatility:** Good news or bad news can result in extreme price movements, far greater than with a typical earnings surprise or disappointment.

Unfertile hunting grounds

When stock returns in an industry are reasonably well dispersed, and the distribution normal as in Figure 10 below, then investors stand at least a 50/50 chance of improving returns through stock selection.

However, that is often not the case in the biotech industry where "losers" often outnumber "winners." Returns are not normally distributed, but rather skewed towards below-average.

For example, the average return from all U.S.-listed Biotech firms for the one-year period ending September 30, 2017 was a gain of 9.9%, but the median return was negative 9.6%. Looked at another way, 227 out of 368 firms (62%) had below-average performance, making it a tough environment for stock pickers (Figure 11). This makes an index-based approach to biotech investing ideal in our opinion, where the few winners will be somewhere among the many losers.

Figure 10: Hypothetical return distribution

*Normal curve*

![Figure 10: Hypothetical return distribution](image)

*Reasonably wide dispersion of returns*

*Note: Hypothetical example for illustrative purposes only. Not based on any actual investment.*

Figure 11: Histogram of 1YR returns

*U.S. Biotech firms*

![Figure 11: Histogram of 1YR returns](image)

*Past performance does not guarantee future results.*

*Source: FactSet as of 9/30/2017 for the 368 firms for which one-year total return data was available.*
**Poliwogg Medical Breakthroughs Index: A Primer for Investors**

**Summary**

A tough environment for stock pickers makes Biotech well-suited for passive index-based investing

---

**Era of blockbuster drugs fades**

Big Pharma often looks to fast-growing biotech firms to help them replace their pipelines as generics gain market share as a result of the patent cliff

---

**Risky development process favors acquisition**

New drug development being a risky, lengthy and expensive process creates an environment favorable to licensing or acquiring new drugs from smaller, R&D-focused biotech firms whose trial data shows promise

---

**PMBI: Focuses on Innovation**

The Poliwogg Medical Breakthroughs Index seeks to capture research and development opportunities in the biotechnology and pharmaceutical industries

---

**Innovation at a Discount**

Investors in firms in the Poliwogg Medical Breakthroughs Index have paid up to 67% less per clinical trial than with the NASDAQ Biotechnology Index

---

**Ideal for Indexing**

A tough environment for stock pickers makes Biotech well-suited for passive index-based investing
Poliwogg Medical Breakthroughs Index: A Primer for Investors

Important considerations

An investor should consider the investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus which contain this and other information call 844.234.5852 or visit www.alpsfunds.com. Read the prospectus carefully before investing.

Shares of Exchange Traded Funds (ETFs) are not individually redeemable and owners of the shares may acquire those shares from the ETF and tender those shares for redemption to the ETF in Creation Units only, see the ETF prospectus for additional information regarding Creation Units. Investors may purchase or sell ETF shares throughout the day through any brokerage account, which will result in typical brokerage commissions.

This fund may not be suitable for all investors.

There are risks involved with investing in ETFs including the loss of money. The Fund is considered non-diversified and as a result may experience great volatility than a diversified fund. The Fund’s investments are concentrated in the pharmaceuticals and biotechnology industries, and underperformance in these areas will result in underperformance in the Fund. Investments in small and micro capitalization companies are more volatile than companies with larger market capitalizations.

Distributed by ALPS Portfolio Solutions Distributor, Inc.

Definitions

Price/Earnings Ratio represents equity securities within the Fund’s portfolio, and is not intended to demonstrate Fund growth, income earned by the Fund, or distributions made by the Fund.

Price/Sales Ratio is the stock price divided by the sales per share for the trailing 12-month period.

Poliwogg Medical Breakthroughs Index (TICKER: PMBI) is designed to capture research and development opportunities in the pharmaceutical industry. PMBI consists of small-cap and mid-cap pharmaceutical and biotechnology stocks listed on US stock exchanges that have one or more drugs in either Phase II or Phase III US FDA clinical trials.

This primer was prepared by AltaVista Research. The information and opinions herein are for general information use only and are based on data obtained from recognized statistical services and other sources believed to be reliable. However, such information has not been verified by AltaVista Research, LLC (“AltaVista”), and we do not make any representations as to its accuracy or completeness. AltaVista does not assume any liability for any loss that may result from the reliance by any person upon any information or opinions it provides. Any statements which are non-factual in nature constitute only current opinions, and are subject to change without notice.

Officers and directors of AltaVista (or one of its affiliates) may have positions in securities referred to herein and may sell any security mentioned herein. AltaVista may from time to time, issue reports based on fundamentals, such as expected trends, as well as reports based on technical factors, such as price and volume movements. Since such reports rely upon different criteria, there may be instances when their conclusions are not in concert.

Neither the information contained in this newsletter or on any AltaVista website, nor any opinion expressed herein is intended as an offer or solicitation with respect to the purchase or sale of any security or as personalized investment advice. For more information please visit ETF Research Center.

Copyright © 2017. AltaVista Research, LLC. Research, LLC. All rights reserved.